Celiac plexus neurolysis in the management of unresectable pancreatic cancer: when and how?

Abstract

Pancreatic cancer is the second most common abdominal cancer in North America with an estimated 20% resectability at diagnosis, and overall 5-year survival of 5%. Pain is common in pancreatic cancer patients with 70%-80% suffering substantial pain. Celiac plexus neurolysis (CPN) is a technique that can potentially improve pain control in pancreatic cancer while preventing further escalation of opioid consumption. CPN is performed by injecting absolute alcohol into the celiac plexus neural network of ganglia. This review sets out to explore the current status of CPN in non-resectable pancreatic cancer. We will examine: (1) the efficacy and safety of percutaneous-CPN and endoscopic ultrasound guided-CPN; (2) specific technique modifications including bilateral (vs central) injections and celiac ganglia neurolysis; and (3) the issue of CPN timing, early at pancreatic cancer diagnosis vs traditional late use as salvage therapy.

Keywords: Celiac plexus neurolysis; Endoscopic ultrasound; Gastrointestinal endoscopy; Opioid; Pain; Pancreatic cancer.

Figures

Figure 1

Three celiac ganglia are demonstrated in each image (arrows). SMA: Superior mesenteric artery.